2020 Revenues ($USD) : $9,014,010,114
2020 Revenues (foreign currencies) : JP¥962,516,000,000
2020 R&D spend : $2,129,172,130
2020 Number of Employees : 16,033
Fiscal Year End : 3/31/2021
Key People : Sunao Manabe, CEO

Japan-based Daiichi Sankyo is a pharmaceutical company developing drugs for oncology, cardiovascular as well as vaccines. It also makes medication for Type 2 diabetes, migraines, iron deficiency anemia, Alzheimer's disease, ulcers, rheumatoid arthritis, pain and epilepsy. The company has also collaborated with AstraZeneca to co-develop DS-1062 as a monotherapy/combination therapy for lung cancer, breast cancer and other cancers. –DK